Eleven Biotherapeutics Gets to the Root of Ophthalmic Diseases

Eleven Biotherapeutics – Abbie Celniker, CEO for Eleven Biotherapeutics, provides the audience at the 5th Annual Ophthalmology Innovation Summit with an update on her company’s progress over the past year. Highlighting their company’s focus on understanding the biology of key targets in ophthalmic diseases and creating protein therapeutics to treat them, Abbie details the current state of key therapies in the company’s product pipeline.



Abbie C. Celniker, PhD

Dr. Celniker brings more than 20 years of proven protein therapeutic expertise to Eleven Biotherapeutics. Prior to joining Eleven, Abbie was CEO of Taligen Therapeutics, which was acquired by Alexion Pharmaceuticals.

View Full Profile